Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma

被引：26

作者：

Arcaini, L ^{[1
]}

Orlandi, E ^{[1
]}

Scotti, M ^{[1
]}

Brusamolino, E ^{[1
]}

Passamonti, F ^{[1
]}

Burcheri, S ^{[1
]}

Colombo, N ^{[1
]}

Vanelli, L ^{[1
]}

Sbalzarini, G ^{[1
]}

Lazzarino, M ^{[1
]}

机构：

[1] Univ Pavia, Policlin San Matteo, Div Hematol, IRCCS, I-27100 Pavia, Italy

来源：

CLINICAL LYMPHOMA | 2004年 / 4卷 / 04期

关键词：

D O I：

10.3816/CLM.2004.n.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Optimal treatment for splenic marginal zone lymphoma (MZL) is not clearly established. Splenectomy has been proposed as the treatment of choice in patients with cytopenias and/or symptoms caused by an enlarged spleen. Splenic MZL, which expresses the CD20 antigen on tumor cell surfaces, is a disease entity candidate to treatment with anti-CD20 monoclonal antibodies. We employed an immunochemotherapy regimen with rituximab/cyclophosphamide/vincristine in 3 patients with splenic MZL who had only a partial response following CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) or CHOP-like therapy. The immunochemotherapy regimen was well tolerated and all patients exhibited complete remission. To our knowledge, this is the first report of splenic MZL showing response to a combination of rituximab with chemotherapy.

引用

页码：250 / 252

页数：3

共 11 条

[1] Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles [J].

Arcaini, L ;

Paulli, M ;

Boveri, E ;

Vallisa, D ;

Bernuzzi, P ;

Orlandi, E ;

Incardona, P ;

Brusamolino, E ;

Passamonti, F ;

Burcheri, S ;

Schena, C ;

Pascutto, C ;

Cavanna, L ;

Margrini, U ;

Lazzarino, M .

CANCER, 2004, 100 (01) :107-115

[2]

Catovsky D, 1999, SEMIN HEMATOL, V36, P148

[3] Splenic marginal zone lymphoma:: clinical characteristics and prognostic factors in a series of 60 patients [J].

Chacón, JI ;

Mollejo, M ;

Muñoz, E ;

Algara, P ;

Mateo, M ;

Lopez, L ;

Andrade, J ;

Carbonero, IG ;

Martínez, B ;

Piris, MA ;

Cruz, MA .

BLOOD, 2002, 100 (05) :1648-1654

[4] Intrasinusoidal bone marrow infiltration: A possible hallmark of splenic lymphoma [J].

Franco, V ;

Florena, AM ;

Campesi, G .

HISTOPATHOLOGY, 1996, 29 (06) :571-575

[5]

Franco V, 2001, CANCER-AM CANCER SOC, V91, P294, DOI 10.1002/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO

[6]

2-W

[7]

LAZZARINO M, SEQUENCE IMMUNOCHEMO

[8] SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES - NATURAL-HISTORY AND RESPONSE TO THERAPY IN 50 CASES [J].

MULLIGAN, SP ;

MATUTES, E ;

DEARDEN, C ;

CATOVSKY, D .

BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (02) :206-209

[9] Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients [J].

Thieblemont, C ;

Felman, P ;

Berger, F ;

Dumontet, C ;

Arnaud, P ;

Hequet, O ;

Arcache, J ;

Callet-Bauchu, E ;

Salles, G ;

Coiffier, B .

CLINICAL LYMPHOMA, 2002, 3 (01) :41-47

[10]

Thomas DA, 2001, BLOOD, V98, p134A

← 1 2 →